TransCode Therapeutics publishes investor presentation on RNA therapeutics, cancer vaccines and oncolytic immunotherapy platforms

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc.

RNAZ

0.00
  • Transcode Therapeutics outlined three oncology platforms, led by tumor-targeted RNA therapeutics, alongside vaccine immunotherapies, immuno-oncolytic agents.
  • Lead candidate TTX-MC138, a microRNA-10b antagomiR delivered via iron oxide nanoparticles, is in an active Phase 2a program.
  • Phase 1a in advanced solid tumors: 16 patients treated, about 86 doses, no dose-limiting toxicities through 4.8 mg/kg.
  • Efficacy signals: 9 of 14 evaluable patients had stable disease; 0 complete responses; 0 partial responses; 3 progressive disease.
  • Funding profile: about USD 100 million net invested since the 2021 IPO through financings and grants; no long-term debt.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.